Obinutuzumab - CISMeF

Preferred Label : Obinutuzumab;

NCIt synonyms : Anti-CD20 Monoclonal Antibody R7159; huMAB(CD20); Afutuzumab;

NCIt definition : A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.;

UNII : O43472U9X8;

CAS number : 949142-50-1;

Drug name : Gazyva;

Molecule name : R-7159; RO 5072759; GA-101; RO-5072759; GA 101; R 7159;

Codes from synonyms : 361;

Details

Origin ID

C70741;

UMLS CUI

C2742503;

Automatic exact mappings (from CISMeF team)
- afutuzumab [MeSH concept]
Currated CISMeF NLP mapping
- Obinutuzumab [ICD-11 Extension code]
- Obinutuzumab [SMS substance]
- Obinutuzumab [Anticorps monoclonal]
- Obinutuzumab (substance) [SNOMED CT concept]
- obinutuzumab [MeSH Supplementary Concept]
- obinutuzumab [MeSH concept]
See also inter- (CISMeF)
- Product containing obinutuzumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Obinutuzumab (substance) [SNOMED CT concept]
- Product containing obinutuzumab (medicinal product) [SNOMED CT concept]
- obinutuzumab [MeSH concept]
- obinutuzumab [ATC Code]
- obinutuzumab [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- obinutuzumab [ATC Code]
chemical_or_drug_affects_cell_type_or_tissue
- B-Lymphocyte [NCIt concept]
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Antibody-Dependent Cellular Cytotoxicity [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD20 [NCIt concept]
is_component_of_chemotherapy_regimen
- Acalabrutinib/Obinutuzumab Regimen [NCIt concept]
- Bendamustine/Obinutuzumab Followed by Obinutuzumab Regimen [NCIt concept]
- Bendamustine/Obinutuzumab Regimen [NCIt concept]
- CVP/Obinutuzumab Regimen [NCIt concept]
- Chlorambucil/Obinutuzumab Regimen [NCIt concept]
- G-CHOP Regimen [NCIt concept]
- Glofitamab/Obinutuzumab Regimen [NCIt concept]
- High-dose Methylprednisolone/Obinutuzumab Regimen [NCIt concept]
- Ibrutinib/Obinutuzumab Regimen [NCIt concept]
- Lenalidomide/Obinutuzumab Followed by Obinutuzumab Regimen [NCIt concept]
- Lenalidomide/Obinutuzumab Regimen [NCIt concept]
- Obinutuzumab Regimen [NCIt concept]
- Obinutuzumab/Vemurafenib Regimen [NCIt concept]
- Obinutuzumab/Venetoclax Regimen [NCIt concept]
- Obinutuzumab/Venetoclax/Zanubrutinib Regimen [NCIt concept]
- Obinutuzumab/Zanubrutinib Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients